A Walloon biotech wants to disrupt cardiovascular prevention - Companies

A Walloon biotech wants to disrupt cardiovascular prevention – Companies

Spinovit is developing a technology to measure a patient’s vascular health from a blood sample. The biotech, created last February, has just raised one million euros.

Preventing cardiovascular disease, the leading cause of death in the world, is the challenge set by the new UCLouvain spin-off, Spinovit. It has developed a device allowing, from a “simple” blood test, to measure the vascular health of a patient and thus to anticipate, for example, the risks of cardiological complications during a surgical intervention.

Preventing cardiovascular disease, the leading cause of death in the world, is the challenge set by the new UCLouvain spin-off, Spinovit. It has developed a device allowing, from a “simple” blood test, to measure the vascular health of a patient and thus to anticipate, for example, the risks of cardiological complications during a surgical intervention. blood vessels produce nitric oxide (NO) molecules, which protect them. “When a person has poor vascular health, their ability to produce nitric oxide decreases, explains Prof. Jean-Luc Balligand, director of the Pharmacology and Therapeutics Pole at UCLouvain. In our laboratory, we have observed that, in the blood, NO binds to hemoglobin to form a complex called HbNO (nitrosylated hemoglobin). Our original idea was to measure this molecule to reflect the health of the vessels”. This idea has been refined for about ten years and it is now taking a step further with the creation, last February, of Spinovit. This biotech has raised one million euros from Vives (UCLouvain’s fund), B2start and the Walloon Region (Wing equity stake and recoverable advance from DGO6). These resources will enable it to complete the ongoing clinical study with 1,500 volunteer patients, in order to confirm the predictability of the cardiovascular biomarker. The results are expected for the end of 2023. A second round of investment should then support the commercial development of the company, from 2024. “We will first target the anesthetist market, specifies Nancy Van Overstraeten, founder and CEO of Spinovit. We provide them with a solution that allows them to measure the cardiovascular risk before an intervention, a risk which, until now, was difficult to quantify.” Spinovit will then offer its test to cardiologists, endocrinologists and pharmaceutical companies. The company’s website already allows people concerned about their cardiovascular health to order a free first test. “The idea is that the patient repeats this test every year to closely monitor the condition of their blood vessels, says Dr. Van Overstraeten. We are part of this trend of patient involvement, encouragement to everyone to take their health into their own hands. This makes it possible to detect cardiovascular diseases earlier. Our test also makes it possible to reinforce patient adherence to treatments which are sometimes heavy. The patient will be able to directly measure the impact of his efforts .” “This is a real revolution for the individualized prevention of cardiovascular risk in the patient, which constitutes a major societal challenge, adds Philippe Durieux, CEO of Vives Fund and Sopartec, the technology transfer and investment company of the “UCLouvain. This solution could prove useful both for people who know they are at risk and for those who are unaware. These may include young people, amateur or high-level athletes.” Spinovit’s solution comes in the form of a kit with, on the one hand, analysis software developed in-house, and on the other, a syringe manufactured in a partner factory in Wallonia.

.

Leave a Comment

Your email address will not be published.